Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses and prices are as of 4 p.m. in New York.
Allscripts Healthcare Solutions Inc. (MDRX US) fell the second-most in the Russell 1000 Index, sliding 9 percent to $19.54. The software maker said it sees profit this year of no more than $1.10 a share, missing the average analyst estimate of $1.11.
Arthrocare Corp. (ARTC US) fell the most in the Russell 2000 Index, dropping 19 percent to $25. The surgical-tool maker reported fourth-quarter sales that missed analysts’ estimates. Jefferies Group Inc. cut the stock’s rating to hold from buy.
Cell Therapeutics Inc. (CTIC US) surged 22 percent to $1.35 for the fourth-biggest increase in the Russell 2000 Index. The European Medicines Agency recommended conditional approval of the company’s Pixuvri treatment for the cancer non-Hodgkin’s B-cell lymphoma.
Demand Media Inc. (DMD US) rallied 31 percent to $7.76 for the biggest gain in the Russell 2000. The online operator of websites eHow.com and LiveStrong.com reported fourth-quarter adjusted profit that topped analysts’ estimates.
First Solar Inc. (FSLR US) rose 7.3 percent to $42.59 for the biggest gain in the Standard & Poor’s 500 Index. The biggest maker of thin-film solar panels resolved a permitting issue with Los Angeles County for a $1.36 billion power project under construction, paving the way for financing to resume.
FreightCar America Inc. (RAIL US) gained 19 percent, the most since July 2005, to $25.33. The maker of railroad freight cars reported fourth-quarter revenue of $187.1 million, beating the average analyst estimate of $128 million.
General Mills Inc. (GIS US) fell 3.6 percent, the most since July 2010, to $38.34. The maker of Cheerios and Green Giant frozen vegetables cut its full-year earnings forecast to $2.55 per share at most after previously seeing as much as $2.61. The projection misses the average analyst estimate of $2.60.
Gilead Sciences Inc. (GILD US) dropped 14 percent, the most in the S&P 500, to $47. The Foster City, California-based biopharmaceutical company said six out of eight participants in a study using its experimental hepatitis C drug showed “viral relapse” within four weeks after stopping a 12-week treatment plan.
Rivals rallied. Vertex Pharmaceuticals Inc. (VRTX US) rose 4.7 percent to $39.24. Achillion Pharmaceuticals Inc. (ACHN US) jumped 26 percent to $11.04. Idenix Pharmaceuticals Inc. (IDIX US) climbed 3.9 percent to $11.91.
H.J. Heinz Co. (HNZ US) rose 4.6 percent, the most since September 2009, to $54.47. The world’s biggest ketchup maker reported third-quarter adjusted earnings of 95 cents per share, beating the average estimate of 85 cents per share. Third-quarter sales of $2.92 billion also beat the average estimate of $2.89 billion.
Life Technologies Corp. (LIFE US) fell 7.8 percent to $45.92, the second-biggest loss in the S&P 500. The provider of gene-analysis tools will face competition from Oxford Nanopore Technologies Ltd., which is entering the gene-sequencing race with a new portable device that will allow people to analyze DNA on the go. The market is also led by Illumina Inc. (ILMN US), which fell 3.9 percent to $51.82.
Maxwell Technologies Inc. (MXWL US) fell 5.3 percent, the most since Nov. 9, to $19.93. The maker of electronic components declined as Robert W Baird & Co. shifted the company to “neutral” from “outperform,” based on lower-than-expected fourth-quarter revenue.
Netspend Holdings Inc. (NTSP US) rose 13 percent to $9.50, the highest price since July 8. The Austin, Texas-based provider of reloadable prepaid debit cards forecast earnings of as much as 55 cents a share this year, above the average analyst estimate of 52 cents.
RealPage Inc. (RP US) slumped 14 percent, the most since it went public in August 2010, to $20.71. The provider of rental-property management software forecast first-quarter profit excluding some items of 10 cents a share, trailing the 11-cent average analyst estimate in a Bloomberg survey.
SunPower Corp. (SPWR US) rose 8.7 percent, the second-most in the Russell 1000, to $8.13. The solar panel company majority-owned by Total SA reported better-than-estimated fourth-quarter earnings and said 2012 sales will be in line with previous forecast.